New insights into inhibitor design from the crystal structure and NMR studies of Escherichia coli GAR transformylase in complex with β-GAR and 10-formyl-5,8,10-trideazafolic acid

被引:42
作者
Greasley, SE
Yamashita, MM
Cai, H
Benkovic, SJ
Boger, DL
Wilson, IA
机构
[1] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[4] Penn State Univ, Dept Chem, University Pk, PA 16802 USA
关键词
D O I
10.1021/bi991888a
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The crystal structure of Escherichia coli GAR Tfase at 2.1 Angstrom resolution in complex with 10-formyl-5,8,10-trideazafolic acid (10-formyl-TDAF, K-i = 260 nM), an inhibitor designed to form an enzyme-assembled multisubstrate adduct with the substrate, beta-GAR, was studied to determine the exact nature of its inhibitory properties. Rather than forming the expected covalent adduct, the folate inhibitor binds as the hydrated aldehyde (gem-diol) in the enzyme active site, in a manner that mimics the tetrahedral intermediate of the formyl transfer reaction. In this hydrated form, the inhibitor not only provides unexpected insights into the catalytic mechanism but also explains the 10-fold difference in inhibitor potency between 10-formyl-TDAF and the corresponding alcohol, and a further 10-fold difference for inhibitors that lack the alcohol. The presence of the hydrated aldehyde was confirmed in solution by C-13-H-1 NMR spectroscopy of the ternary GAR Tfase-beta-GAR-10-formyl-TDAF complex using the C-13-labeled-10-formyl-TDAF. This insight into the behavior of the inhibitor, which is analogous to protease or transaminase inhibitors, provides a novel and previously unrecognized basis for the design of more potent inhibitors of the folate-dependent formyl transfer enzymes of the purine biosynthetic pathway and development of anti-neoplastic agents.
引用
收藏
页码:16783 / 16793
页数:11
相关论文
共 52 条
[1]   STRUCTURES OF APO AND COMPLEXED ESCHERICHIA-COLI GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE [J].
ALMASSY, RJ ;
JANSON, CA ;
KAN, CC ;
HOSTOMSKA, Z .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (13) :6114-6118
[2]  
[Anonymous], ACTA CRYSTALLOGR D
[3]   Substrate specificity of glycinamide ribonucleotide transformylase from chicken liver [J].
Antle, VD ;
Liu, DS ;
McKellar, BR ;
Caperelli, CA ;
Hua, M ;
Vince, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) :6045-6049
[4]  
BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328
[5]   Functionalized analogues of 5,8,10-trideazafolate: Development of an enzyme-assembled tight binding inhibitor of GAR Tfase and a potential irreversible inhibitor of AICAR Tfase [J].
Boger, DL ;
Haynes, NE ;
Warren, MS ;
Ramcharan, J ;
Kitos, PA ;
Benkovic, SJ .
BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (09) :1839-1846
[6]   Abenzyl 10-formyl-trideazafolic acid (Abenzyl 10-formyl-TDAF): An effective inhibitor of glycinamide ribonucleotide transformylase [J].
Boger, DL ;
Haynes, NE ;
Warren, MS ;
Ramcharan, J ;
Marolewski, AE ;
Kitos, PA ;
Benkovic, SJ .
BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (09) :1847-1852
[7]   Multisubstrate analogue based on 5,8,10-trideazafolate [J].
Boger, DL ;
Haynes, NE ;
Warren, MS ;
Ramcharan, J ;
Kitos, PA ;
Benkovic, SJ .
BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (09) :1853-1857
[8]   10-formyl-5,8,10-trideazafolic acid (10-formyl-TDAF): A potent inhibitor of glycinamide ribonucleotide transformylase [J].
Boger, DL ;
Haynes, NE ;
Kitos, PA ;
Warren, MS ;
Ramcharan, J ;
Marolewski, AE ;
Benkovic, SJ .
BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (09) :1817-1830
[9]   Functionalized analogues of 5,8,10-trideazafolate as potential inhibitors of GAR Tfase or AICAR Tfase [J].
Boger, DL ;
Haynes, NE ;
Warren, MS ;
Gooljarsingh, LT ;
Ramcharan, J ;
Kitos, PA ;
Benkovic, SJ .
BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (09) :1831-1838
[10]   AG2034: A novel inhibitor of glycinamide ribonucleotide formyltransferase [J].
Boritzki, TJ ;
Barlett, CA ;
Zhang, C ;
Howland, EE ;
Margosiak, SA ;
Palmer, CL ;
Romines, WH ;
Jackson, RC .
INVESTIGATIONAL NEW DRUGS, 1996, 14 (03) :295-303